Drug Information
Drug (ID: DG00499) and It's Reported Resistant Information
Name |
Sulfamethizole/Sulfadiazine
|
||||
---|---|---|---|---|---|
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Cholera [ICD-11: 1A00]
[1]
|
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Cholera [ICD-11: 1A00]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Dihydrofolate reductase (DHFR) | [1] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae O62 strain AS438 | 666 | ||
Vibrio cholerae PG149a | 666 | |||
Vibrio cholerae PG224 | 666 | |||
Vibrio cholerae PG262(b) | 666 | |||
Vibrio cholerae PG9 | 666 | |||
Vibrio cholerae PG95 | 666 | |||
Vibrio cholerae PL1 | 666 | |||
Vibrio cholerae PL61 | 666 | |||
Vibrio cholerae PL78/6 | 666 | |||
Vibrio cholerae PL91 | 666 | |||
Vibrio cholerae PL105b | 666 | |||
Vibrio cholerae PL141 | 666 | |||
Vibrio cholerae PG92 | 666 | |||
Vibrio cholerae PL134 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA1 lead to drug resistance. | |||
Key Molecule: AAC(6')-Ib family aminoglycoside 6'-N-acetyltransferase (AAC6IB) | [1] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PL107b | 666 | ||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of aac(6')-Ib lead to drug resistance. | |||
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) | [1] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae O26 strain AS482 | 567107 | ||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of aadA1-S lead to drug resistance. | |||
Key Molecule: Dihydrofolate reductase (DHFR) | [1] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA15 lead to drug resistance. | |||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Erythromycin esterase (EREA2) | [1] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.